We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE)/ BioNTech to Supply Extra Comirnaty Doses to EU
Read MoreHide Full Article
Pfizer Inc. (PFE - Free Report) and its partner BioNTech SE (BNTX - Free Report) announced that they will supply an additional 100 million doses of their COVID-19 vaccine, Comirnaty, to the 27 European Union (“EU”) member states in the ongoing year.
The companies agreed to do the same after the European Commission (“EC”) exercised its option to purchase an additional 100 million doses of Comirnaty, bringing the total tally to 600 million doses, all of which are expected to delivered by the end of 2021.
Please note that, in February 2021, Pfizer/BioNTech announced a deal with the EC to supply additional 200 million doses of Comirnaty. The deal also gave an option to the EC to request for an additional 100 million doses of the COVID-19 vaccine which the regulatory body has exercised now. Pfizer/BioNTech had signed the first supply agreement with EC last year to supply 300 million doses.
We note that, Comirnaty/BNT162b2, a two-shot vaccine for COVID-19, is now approved for emergency/temporary use in several countries worldwide.
Shares of Pfizer have rallied 5.8% so far this year compared with the industry’s increase of 1.8%.
Reportedly, the EU has been hit by some setbacks in connection to the supply of AstraZeneca (AZN - Free Report) and J&J (JNJ - Free Report) vaccines shots. Vaccines of both these companies are facing trouble over blood clot issues in vaccinated people. This might have triggered the increased order for the Pfizer/BioNTech vaccine in the EU.
Please note that J&J and AstraZeneca’s vaccines have been developed using adenovirus technologies while the other two vaccines which have been launched – Pfizer/BioNTech’s BNT162b2 and Moderna’s mRNA-1273 –are mRNA-based vaccines.
Pfizer/BioNTech and Moderna have had a competitive advantage as their two-shot mRNA-based vaccines were launched toward the end of 2020, much earlier than AstraZeneca and J&J’s jabs. Meanwhile, Pfizer/BioNTech and Moderna’s vaccines were about 95% effective in clinical trials. AstraZeneca’s vaccine was, on average, about 76% effective in preventing COVID-19. J&J’s single-shot vaccine was about 66% effective in preventing COVID-19.
Some investors are of the opinion that Moderna and Pfizer/BioNTech may gain additional market share from safety issues related with J&J and AstraZeneca’s COVID-19 vaccines. No clot cases have been reported in people who have received either the Pfizer or the Moderna vaccine.
+1,500% Growth: One of 2021’s Most Exciting Investment Opportunities
In addition to the stocks you read about above, would you like to see Zacks’ top picks to capitalize on the Internet of Things (IoT)? It is one of the fastest-growing technologies in history, with an estimated 77 billion devices to be connected by 2025. That works out to 127 new devices per second.
Zacks has released a special report to help you capitalize on the Internet of Things’s exponential growth. It reveals 4 under-the-radar stocks that could be some of the most profitable holdings in your portfolio in 2021 and beyond.
Image: Bigstock
Pfizer (PFE)/ BioNTech to Supply Extra Comirnaty Doses to EU
Pfizer Inc. (PFE - Free Report) and its partner BioNTech SE (BNTX - Free Report) announced that they will supply an additional 100 million doses of their COVID-19 vaccine, Comirnaty, to the 27 European Union (“EU”) member states in the ongoing year.
The companies agreed to do the same after the European Commission (“EC”) exercised its option to purchase an additional 100 million doses of Comirnaty, bringing the total tally to 600 million doses, all of which are expected to delivered by the end of 2021.
Please note that, in February 2021, Pfizer/BioNTech announced a deal with the EC to supply additional 200 million doses of Comirnaty. The deal also gave an option to the EC to request for an additional 100 million doses of the COVID-19 vaccine which the regulatory body has exercised now. Pfizer/BioNTech had signed the first supply agreement with EC last year to supply 300 million doses.
We note that, Comirnaty/BNT162b2, a two-shot vaccine for COVID-19, is now approved for emergency/temporary use in several countries worldwide.
Shares of Pfizer have rallied 5.8% so far this year compared with the industry’s increase of 1.8%.
Reportedly, the EU has been hit by some setbacks in connection to the supply of AstraZeneca (AZN - Free Report) and J&J (JNJ - Free Report) vaccines shots. Vaccines of both these companies are facing trouble over blood clot issues in vaccinated people. This might have triggered the increased order for the Pfizer/BioNTech vaccine in the EU.
Please note that J&J and AstraZeneca’s vaccines have been developed using adenovirus technologies while the other two vaccines which have been launched – Pfizer/BioNTech’s BNT162b2 and Moderna’s mRNA-1273 –are mRNA-based vaccines.
Pfizer/BioNTech and Moderna have had a competitive advantage as their two-shot mRNA-based vaccines were launched toward the end of 2020, much earlier than AstraZeneca and J&J’s jabs. Meanwhile, Pfizer/BioNTech and Moderna’s vaccines were about 95% effective in clinical trials. AstraZeneca’s vaccine was, on average, about 76% effective in preventing COVID-19. J&J’s single-shot vaccine was about 66% effective in preventing COVID-19.
Some investors are of the opinion that Moderna and Pfizer/BioNTech may gain additional market share from safety issues related with J&J and AstraZeneca’s COVID-19 vaccines. No clot cases have been reported in people who have received either the Pfizer or the Moderna vaccine.
Zacks Rank
Pfizer currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
+1,500% Growth: One of 2021’s Most Exciting Investment Opportunities
In addition to the stocks you read about above, would you like to see Zacks’ top picks to capitalize on the Internet of Things (IoT)? It is one of the fastest-growing technologies in history, with an estimated 77 billion devices to be connected by 2025. That works out to 127 new devices per second.
Zacks has released a special report to help you capitalize on the Internet of Things’s exponential growth. It reveals 4 under-the-radar stocks that could be some of the most profitable holdings in your portfolio in 2021 and beyond.
Click here to download this report FREE >>